HALT-C Publications

  1. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE. Peginterferon Alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004 Apr;126(4):1015-23.

    Download a summary of this paper

  2. Morishima C, Chung M, Ng KW, Brambilla DJ, Gretch DR. Strengths and limitations of commercial tests for hepatitis C virus RNA quantification. J Clin Microbiol. 2004 Jan;42(1):421-5.
  3. Rothman AL, Morishima C, Bonkovsky HL, Polyak SJ, Ray R, Di Bisceglie AM, Lindsay KL, Malet PF, Chang M, Gretch DR, Sullivan DG, Bhan AK, Wright EC, Koziel MJ; HALT-C Trial Group. Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology. 2005 Mar;41(3):617-25
  4. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky, HL, Shiffman ML, Everson GT, Di Bisceglie AM, Morgan TR, Ghany MG, Morishima C, Wright ED, Everhart JE Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders Controlled Clinical Trials, Volume 25, Issue 5, October 2004, Pages 472-492
  5. Robert J. Fontana, Linas A. Bieliauskas, Carla Back-Madruga, Karen L. Lindsay, Ziad Kronfol, Anna S. Lok, Latha Padmanabhan, the HALT-C Trial Group Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial Journal of Hepatology. Volume 43, Issue 43 , October 2005, Pages 614-622
  6. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Dienstag JL, Morishima C. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: Results of the HALT-C cohort. Hepatology. 2005 Aug;42(2):282-92.
  7. Adrian M. Di Bisceglie, Richard K. Sterling, Raymond T. Chung, James E. Everhart, Jules L. Dienstag, Herbert L. Bonkovsky, Elizabeth C. Wright, Gregory T. Everson, Karen L. Lindsay, Anna S.F. Lok, William M. Lee, Timothy R. Morgan, Marc G. Ghany, David R. Gretch and the HALT-C Trial Group Serum alpha-fetoprotein levels in patients with advanced hepatitis C: Results from the HALT-C Trial Journal of Hepatology. Volume 43, Issue 3 , September 2005, Pages 434-441.
  8. Bieliauskas LA, Back-Madruga C, Lindsay KL, Snow KK, Kronfol Z, Lok AS, Padmanabhan L, Fontana RJ, HALT-C Trial Group. Clinical Relevance of Cognitive Scores in Hepatitis C Patients with Advanced Fibrosis. Journal of Clinical and Experimental Neuropsychology, Volume 28, Number 8 / Nov 2006, Pages 1346 - 1361.
  9. Polyak SJ, Sullivan DG, Austin MA, Dai JY, Shuhart MC, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morishima C, Gretch DR Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis Virol J. 2005 Apr 22;2(1):41
  10. Sanyal AJ, Fontana RJ, Di Bisceglie AM, Everhart JE, Doherty MC, Everson GT, Donovan JA, Malet PF, Mehta S, Sheikh MY, Reid AE, Ghany MG, Gretch DR, The HALT-C Trial Group. The Prevalence and Risk Factors Associated with Esophageal Varices in Subjects with Hepatitis C and Advanced Fibrosis. GI Endoscopy, 2006 Dec; 64(6):855-864.
  11. Morishima C, Polyak SJ, Ray R, Doherty MC, Di Bisceglie AM, Malet PF, Bonkovsky HL, Sullivan DG, Gretch DR, Rothman AL, Koziel MJ, Lindsay KL, and the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis Trial Group. Hepatitis C Virus-Specific Immune Responses and Quasi-Species Variability at Baseline Are Associated with Nonresponse to Antiviral Therapy during Advanced Hepatitis C. J Infect Dis, 2006 Apr;193(7):931-40.
  12. Fontana RJ, Sanyal AJ, Mehta S, Doherty MC, Neuschwander-Tetri BA, Everson GT, Kahn JA, Malet PF, Sheikh MY, Chung RT, Ghany MG, Gretch DR; the HALT-C Trial Group. Portal Hypertensive Gastropathy in Chronic Hepatitis C Patients with Bridging Fibrosis and Compensated Cirrhosis: Results from the HALT-C Trial. Am J Gastroenterol. 2006 Mar 30
  13. Lok ASF, Everhart JE, Chung RT, Padmanabhan L, Greenson JK, Shiffman ML, Everson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Ghany MG, Morishima C, HALT-C Trial Group. Hepatic steatosis in hepatitis C: Comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol. 2007 Feb; 5(2) 245-54.
  14. Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, Kulig CC, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG, Gretch DR, HALT-C Trial Group. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007 Mar; 46(3):420-31. Epub 2006 Nov
  15. Lindsay KL, Morishima C, Wright EC, Dienstag JL, Shiffman ML, Everson GT, Lok AS, Bonkovsky HL, Lee WM, Morgan TR, Ghany MG; HALT-C Trial. Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C.Clin Gastroenterol Hepatol. 2008 Feb;6(2):234-41.
  16. Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, Lindsay KL, Lok ASF, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Gretch DR, and the HALT-C Trial Group. HCV RNA Detection by TMA During the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 2005; 44: 360-367.
  17. Bonkovsky HL, Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR, Rogers TE, Banner BF, Sterling RK, Donovan JA, Fontana RJ, Di Bisceglie AM, Ghany MG, Morishima C, and the HALT-C Trial Group. Influence of Iron and HFE Mutations on Severity and Response to Therapy during Retreatment of Advanced Chronic Hepatitis C in the HALT-C Trial. Gastroenterology 2006; 131: 1440-1451.
  18. Everson GT, Shiffman ML, Morgan TR, Hoefs JC, Sterling RK, Wagner DA, Kulig CC, Curto TM, Wright EC, HALT-C Trial Group. The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the HALT-C trial. Aliment Pharmacol Ther. 2008 May; 27(9): 798-809.
  19. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok ASF, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C, and the HALT-C Trial Group. Impact of Disease Severity on Outcome of Antiviral Therapy for Chronic Hepatitis C: Lessons from the HALT-C Trial. Hepatology 2006 Dec; 44(6):1675-92.
  20. Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, Lok ASF, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Gretch DR, and the HALT-C Trial Group. Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C. Gastroenterology, 2007 Jan; 132(1):103-12.
  21. Bieliauskas LA, Back-Madruga C, Lindsay KL, Wright EC, Kronfol Z, Lok ASF, Fontana RJ, HALT-C Trial Group. Cognitive reserve and neuropsychological functioning in patients infected with hepatitis C. Journal of the International Neuropsychological Society, 2007 13: 1-6.
  22. Fontana RJ, Bieliauskas LA, Lindsay KL, Back-Madruga C, Wright EC, Snow KK, Lok ASF, Kronfol Z, Padmanabhan L, HALT-C Trial Group. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Hepatology. 2007 May;45(5):1154-63.
  23. Everson GT, Martucci MA, Shiffman ML, Sterling RK, Morgan TR, Hoefs JC, The HALT-C Trial Group. Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate shunt clearances and shunt. Alimentary Pharmacology & Therapeutics. 2007 Aug 1;26(3):401-10.
  24. Fontana RJ, Kronfol Z, Lindsay KL, Bieliauskas LA, Padmanabhan L, Back-Madruga C, Lok ASF, Stoddard AM, and the HALT-C Trial Group. Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C. American Journal of Gastroenterology. 2008; 103:2766-2775.
  25. Pierucci-Lagha A, Covault J, Bonkovsky HL, Feinn R, Abreu C, Sterling RK, Fontana RJ, Kranzler HR, and the HALT-C Trial Group. A Functional Serotonin Transporter Gene Polymorphism and Depressive Effects Associated with Interferon-∝ Treatment. Psychosomatics. 2010 Mar-Apr;51(2):137-48.
  26. Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, Su GL, Ghosh M, Wright EC; HALT-C Trial Group. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology. 2008 Jan 3;47(3):789-798.
  27. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, Lindsay KL, Lok AS, Di Bisceglie AM, Lee WM, Ghany MG; HALT-C Trial Group. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology. 2008 Feb;47(2):605-12.
  28. Morishima C, Morgan TR, Everhart JE, Wright EC, Apodaca MC, Gretch DR, Shiffman ML, Everson GT, Lindsay KL, Lee WM, Lok AS, Dienstag JL, Ghany MG, Curto TM; HALT-C Trial Group. Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology. 2008 Nov;48(5):1412-9.
  29. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL, for the HALT-C Trial Investigators. Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon. New England Journal of Medicine 2008 Dec;359(23):2429-41.
  30. Morgan TR, Lambrecht RW, Bonkovsky HL, Chung RT, Naishadham D, Sterling RK, Fontana RJ, Lee WM, Ghany MG, Wright EC, O'Brien TR, and the HALT-C Trial Group. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: Results from the HALT-C trial. Journal of Hepatology. 2008 Oct; 49(4): 548-556.
  31. Bell MC, Robuck PR, Wright EC, Mihova MS, Hofmann C, De Santo JL, Milstein SL, Richtmyer PA, Shelton JL, Cormier M, King DL, Park CJ, Molchen WA, Park Y, Kelley M, and the HALT-C Trial Group. Automated Summaries of Serious Adverse Events in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis Trial. Clinical Trials. 2009 Dec;6(6):618-27. Epub 2009 Nov 4.
  32. Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, Di Bisceglie AM, Ghany MG, Gretch DR, Chanock SJ, Chung RT, O’Brien TR, the HALT-C Trial Group. Variants in Interferon-Alpha Pathway Genes and Response to Pegylated Interferon-Alpha2a Plus Ribavirin for Treatment of Chronic Hepatitis C Virus Infection in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. Hepatology. 2009 Jun;49(6):1847-58.
  33. Everson GT, Shiffman, ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA, DeSanto JL, Curto TM, Wright EC, and the HALT-C Trial Group. Quantitative Tests of Liver Function Measure Hepatic Improvement after Sustained Virologic Response: Results from the HALT-C Trial. Aliment Pharmacol Ther. 2009 Mar; 29(5): 589-601.
  34. Lok AS, Seeff LB, Morgan TR, Di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD, and the HALT-C Trial Group. Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease. Gastroenterology 2009 Jan; 136(1):138-148.
  35. Yuan HJ, Jain M, Snow KK, Gale M, Lee WM, and the HALT-C Trial Group. Evolution of Hepatitis C Virus NS5A Region in Breakthrough Patients During Pegylated Interferon and Ribavirin Therapy. J of Viral Hepat 2010 Mar 1: 17(3):208-16. Epub 2009 July 28.
  36. Fontana RJ, Bonkovsky HL, Naishadham D, Dienstag JL, Sterling RK, Lok ASF, Su GL, and the HALT-C Trial Group. Serum Fibrosis Marker Levels Decrease After Successful Antiviral Treatment in Chronic Hepatitis C Patients With Advanced Fibrosis. Clin Gastroenterol Hepatol. 2009 Feb; 7(2) 219-226.
  37. Lok AS, Everhart JE, Chung RT, Kim H-Y, Everson GT, Hoefs JC, Greenson JK, Sterling, RK, Lindsay KL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Ghany MG, Morishima C, and the HALT-C Trial Group. Evolution of Hepatic Steatosis in Patients with Advanced Hepatitis C: Results from the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology. 2009 Jun;49(6):1828-37.
  38. Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R, HALT-C Trial Group. Coffee Intake is Associated with Lower Rates of Liver Disease Progression in Chronic Hepatitis C. Hepatology. 2009 Nov;50(5):1360-9.
  39. Everhart JE, Lok AS, Kim HY, Morgan TR, Lindsay KL, Chung RT, Bonkovsky HL, Ghany MG, and the HALT-C Trial Group. Weight Related Effects on Disease Progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis Trial. Gastroenterology 2009 Aug; 137(2):549-57.
  40. Ghany MG, Lok ASF, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan TR, Dienstag JL and the HALT-C Trial Group. Predicting Clinical and Histological Outcomes Based on Standard Laboratory Tests in Advanced Chronic Hepatitis C. Gastroenterology 2010 Jan; 138(1):136-46. Epub 2009 Sep 17.
  41. Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG, and the HALT-C Trial Group. Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial. Gastroenterology 2009 Dec; 137(6):1986-94. Epub 2009 Sep 10.
  42. Goodman ZD, Stoddard AM, Bonkovsky HL, Fontana RJ, Ghany MG, Morgan TR, Wright EC, Brunt EM, Kleiner DE, Shiffman ML, Everson GT, Lindsay KL, Dienstag JL, Morishima C, and the HALT-C Trial Group. Fibrosis Progression in Chronic Hepatitis C: Morphometric Image Analysis in the HALT-C Trial. Hepatology. 2009 Dec;50(6):1738-49.
  43. Fontana RJ, Bieliauskas LA, Back-Madruga C, Lindsay KL, Litman HJ, Lok AS, Kronfol Z, and the HALT-C Trial Group. Cognitive Function Does Not Worsen During Long-Term Low-Dose Peginterferon Therapy in Patients With Chronic Hepatitis C. Am J Gastroenterol. 2010 Jul;105(7):1551-60. Epub 2010 Jan 26.
  44. Snow KK, Bonkovsky HL, Fontana RJ, Kim H-Y, Sterling RK, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG, and the HALT-C Trial Group. Changes in Quality of Life and Sexual Health are Associated with Low-Dose Peginterferon Therapy and Disease Progression in Patients with Chronic Hepatitis C. 2010 Mar; 31(7): 719-734. Epub 2010 Jan 12.
  45. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL, and the HALT-C Trial Group. Des-gamma-Carboxy Prothrombin and alpha-Fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma.  Gastroenterology. 2010 Feb;138(2):493-502. Epub 2009 Oct 20. (view the video )
  46. Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, Shiffman ML, Fontana RJ, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, and the HALT-C Trial Group. Complication Rate of Percutaneous Liver Biopsies Among Persons with Advanced Chronic Liver Disease in the HALT-C Trial. Clin Gastroenterol Hepatol 2010 Oct;8(10):977-83. Epub 2010 Apr 1. (listen to the podcast )
  47. Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE, Ghany MG, Mills AS, Nash SR, Govindarajan S, Rogers TE, Greenson JK, Brunt EM, Bonkovsky HL, Morishima C, Litman HJ, and the HALT-C Trial Group. Prognostic Value of Ishak Fibrosis Stage: Findings from the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. Hepatology. 2010 Dec;51(2):585-94.
  48. Fontana RJ, Sanyal AJ, Ghany MG, Lee WM, Reid AE, Naishadham D, Everson GT, Kahn JA, Di Bisceglie AM, Szabo G, Morgan TR, Everhart JE, and the HALT-C Trial Group. Factors that Determine the Development and Progression of Gastroesophageal Varices in Patients With Chronic Hepatitis C. Gastroenterol 2010 Jun;138(7):2321-31.e1-2. Epub 2010 Mar 6.
  49. Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL, and the HALT-C Trial Group. Serum Fibrosis Markers are Associated with Liver Disease Progression in Non-Responder Patients with Chronic Hepatitis C. Gut 2010 Oct;59(10):1401-1409. Epub 2010 Jul 30.
  50. Lambrecht RW, Sterling RK, Naishadham D, Stoddard AM, Rogers T, Morishima C, Morgan TR, Bonkovsky HL, and the HALT-C Trial Group. Iron Levels in Hepatocytes and Portal Tract Cells Predict Progression and Outcomes of Patients With Advanced Chronic Hepatitis C. Gastroenterology. 2011 May;140(5):1490-1500.e3. Epub 2011 Feb 15.
  51. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS, and the HALT-C Trial Group. Outcome of Sustained Virological Responders with Histologically Advanced Chronic Hepatitis C. Hepatology 2010 Sep;52(3):833-44. Epub 2010 May 10.
  52. Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS, Di Bisceglie AM, Ghany MG, Naishadham D, Morgan TR, Wright EC, and the HALT-C Trial Group. Reduction in Hepatic Inflammation is associated with less Fibrosis Progression and fewer Clinical Outcomes in Advanced Hepatitis C. Am J Gastroenterol. 2012 Jun 12. doi: 10.1038/ajg.2012.137. [Epub ahead of print]
  53. Morishima C, Di Bisceglie AM, Rothman AL, Bonkovsky HL, Lindsay KL, Lee WM, Koziel MJ, Fontana RJ, Kim HY, Wright EC. Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C. J Viral Hepat. 2012 Jun;19(6):404-413. doi: 10.1111/j.1365-2893.2011.01562.x. Epub 2011 Dec 16.
  54. O'Brien TR, Everhart JE, Morgan TR, Lok AS, Chung RT, Shao Y, Shiffman ML, Dotrang M, Sninsky JJ, Bonkovsky HL, Pfeiffer RM. An IL28B Genotype-Based Clinical Prediction Model for Treatment of Chronic Hepatitis C. PLoS One. 2011;6(7):e20904. Epub 2011 Jul 8.
  55. Freedman ND, Curto TM, Morishima C, Seeff LB, Goodman ZD, Wright EC, Sinha R, Everhart JE, and the HALT-C Trial Group. Silymarin Use and Liver Disease Progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis Trial. Aliment Pharmacol Ther 2011 Jan;33(1):127-137. Epub 2010 Nov 2.
  56. Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE. A prospective study of the rate of progression in compensated histologically advanced chronic hepatitis C. Hepatology. 2011 Aug;54(2):396-405. doi: 10.1002/hep.24370. Epub 2011 Jun 23.
  57. Kronfol Z, Litman HJ, Back-Madruga C, Bieliauskas LA, Lindsay KL, Lok AS, Fontana RJ, the HALT-C Trial Group. No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C. J Affect Disord 2011; 129: 205-212. Epub 2010 Oct 1.
  58. Abu Dayyeh BK, Yang M, Dienstag JL, Chung RT. The Effects of Angiotensin Blocking Agents on Progression of Liver Fibrosis in the HALT-C Trial Cohort. Dig Dis Sci 2011 Feb;56(2)564-8. Epub 2010 Dec 7.
  59. Corey KE, Zheng H, Mendez-Navarro J, Delgado-Borrego A, Dienstag JL, Chung RT. Serum Vitamin D Levels Are Not Predictive of the Progression of Chronic Liver Disease in Hepatitis C Patients with Advanced Fibrosis. PLoS One. 2012;7(2):e27144. Epub 2012 Feb 16.
  60. Fontana RJ, Sanyal AJ, Ghany MG, Bonkovsky HL, Morgan TR, Litman HJ, Reid AE, Lee WM, Naishadham D. Development and Progression of Portal Hypertensive Gastropathy in Patients with Chronic Hepatitis C. Am J Gastroenterol. 2011 May;106(5):884-93. Epub 2010 Dec 7.
  61. O'Bryan JM, Potts JA, Bonkovsky HL, Mathew A, Rothman AL; for the HALT-C Trial Group. Extended Interferon-Alpha Therapy Accelerates Telomere Length Loss in Human Peripheral Blood T Lymphocytes. PLoS One. 2011;6(8):e20922. Epub 2011 Aug 4.
  62. Hoefs JC, Shiffman ML, Goodman ZD, Kleiner DE, Dienstag JL, Stoddard AM. Rate of Progression of Hepatic Fibrosis in Patients with Chronic Hepatitis C: Results from the HALT-C Trial. Gastroenterology. 2011 Sep;141(3):900-908.e2. Epub 2011 Jun 12.12.
  63. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR, HALT-C Trial Group. Maintenance Peginterferon Therapy and Other Factors Associated with Hepatocellular Carcinoma in Patients with Advanced Hepatitis C. Gastroenterol 2011 Mar;140(3):840-849. Epub 2010 Dec 1.
  64. Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan TR, Ghany MG; for the HALT-C Trial Group. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology. 2011 Apr;53(4):1100-1108.
  65. Rakoski MO, Brown MB, Fontana RJ, Bonkovsky HL, Brunt EM, Goodman ZD, Lok AS, Omary MB. Mallory-Denk Bodies Are Associated With Outcomes and Histologic Features in Patients With Chronic Hepatitis C. Clin Gastroenterol Hepatol. 2011 Oct;9(10):902-909.e1. Epub 2011 Jul 23. (view the video )
  66. Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS. Frequency of Elevated Hepatocellular Carcinoma (HCC) Biomarkers in Patients With Advanced Hepatitis C. Am J Gastroenterol. 2012 Jan;107(1):64-74. doi: 10.1038/ajg.2011.312 [Epub ahead of print]
  67. Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology. 2011 Aug;54(2):434-42. doi: 10.1002/hep.24257. Epub 2011 Mar 03.
  68. Everson GT, Shiffman ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA, Lauriski S, Curto TM, Stoddard A, Wright EC. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: Results from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2012 Apr;55(4):1019-1029. doi: 10.1002/hep.24752. Epub 2012 Mar 1.
  69. Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, O'Brien TR, Dienstag JL, Tanabe KK, Chung RT. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology. 2011 Jul;141(1):141-9. Epub 2011 Mar 24.
  70. Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology. 2011 Jun;140(7):1961-9. Epub 2011 Mar 2.
  71. Ghany MG, Kim HY, Stoddard A, Wright EC, Seeff LB, Lok AS. Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology. 2011 Nov;54(5):1527-1537.
  72. Fontana RJ, Litman HJ, Dienstag JL, Bonkovsky HL, Su G, Sterling RK, Lok AS. YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver Int. 2012 Apr;32(4):665-674. doi: 10.1111/j.1478-3231.2011.02686.x.